Published in Cancer Weekly, May 12th, 2009
“The current stimulus package has significantly increased funding for NIH grants,” commented Advaxis CEO Thomas A. Moore. “We have been the fortunate recipient of a multitude of NIH grants. We believe the proposals hold great promise.” About Advaxis Vaccines HER-2 Antigen: The Company’s HER-2 vaccine is based upon a chimeric assembly of many internal and external immune epitopes found to be effective anti-cancer targets. Although never before used...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.